Threat Interpretation Bias as Cognitive Marker and Treatment Target in Pediatric Anxiety: R33 Phase
2026年9月9日 更新者：Michelle Rozenman、University of Denver
Anxiety is chronic, debilitating, and the most common mental health problem across development, costing the U.S. over $42 billion annually.
This phased innovation grant will test a symptom-personalized cognitive bias modification for interpretation bias (CBM-I) as a mechanistic intervention to reduce interpretation bias and, subsequently, anxiety, in clinically anxious youth.
In this R33 trial, participants will be youth ages 10 to 17 (N=72) with a primary "big three" anxiety disorder (i.e., Generalized, Separation, Social).
Youth will be randomly assigned to receive either 16 sessions of personalized CBM-I (the optimal dose identified in the R61 Phase of this study) or equivalent time (four one-hour sessions) over four weeks of a cognitive restructuring (CR), intervention.
Both interventions aim to modify threat-focused thinking.
Please note that the first phase of the trial (R61: NCT04245501 under NIMH award R61MH121552) has been completed and currently this record summary only reflects the R33 phase.
調査の概要
状態
募集
条件
詳細な説明
Anxiety is chronic, debilitating, and the most common mental health problem across development, costing the U.S. over $42 billion annually.
As anxiety disorders most commonly onset before age 18, the period from childhood through adolescence offers a critical window within which to intervene.
Unfortunately, evidence-based interventions are costly, not widely available, and ineffective for upwards of 50% of youth.
In response, pediatric anxiety experts and the National Institute of Mental Health (NIMH) have called for approaches that directly target underlying mechanisms to improve treatments for anxious youth.
One such putative mechanism is interpretation bias - the appraisal of environmental ambiguity as threatening.
Interpretation bias has been identified as a mechanism underlying the development and maintenance of youth anxiety.
We have found that interpretation bias for threat, objectively measured with a paradigm that assesses whether and how quickly youth respond to ambiguous stimuli with threatening appraisals, occurs in 90% of clinically anxious youth, predicts anxiety severity above and beyond clinical characteristics, and differentiates anxious from non-anxious youth.
CBM-I is a computerized intervention that attempts to reduce anxiety by directly targeting and reducing interpretation bias.
While findings in the child literature are preliminary, studies with adults provide initial support that CBM-I at high dose (i.e., more than a few trainings) may reduce anxiety.
This phased innovation grant tests personalized CBM-I in youth ages 10 to 17 who meet diagnostic criteria for a primary anxiety disorder (Generalized, Separation, Social).
In the previous R61 Phase (N=50), a randomized clinical trial (RCT) examined whether CBM-I personalized to youth anxiety symptoms significantly reduced interpretation bias compared to a computerized interpretation control condition (ICC) and identified the optimal dose for reduction in interpretation bias.
The R61 trial results indicated that CBM-I outperforms ICC on interpretation bias reduction, so the current R33 phase will proceed.
In this R33 Phase, an RCT (N=72) will validate whether CBM-I significantly reduces interpretation bias, and conducts a mechanism test (i.e., does bias reduction precede and predict anxiety reduction?), by comparing CBM-I to CR, a clinically relevant psychosocial intervention that also targets anxious cognition.
研究の種類
介入
入学 (推定)
72
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Michelle Rozenman, Ph.D.
- 電話番号：303-871-6448
- メール：bravelab@du.edu
研究場所
-
-
Colorado
-
Denver、Colorado、アメリカ、80210
- 募集
- University of Denver
-
主任研究者：
- Michelle Rozenman, Ph.D.
-
コンタクト：
- Michelle Rozenman, Ph.D.
- 電話番号：303-871-6448
- メール：bravelab@du.edu
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 子
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Provision of signed and dated informed consent form by parent/legal guardian and signed youth assent. If youth turns 18 after study entry (i.e., Visit 1), they will need to reconsent as an adult to continue participation. Youth and consenting parent/legal guardian agree to 6-week study participation as part of consent/assent process.
- Youth and parent/legal guardian speak sufficient English to engage in study procedures.
- Youth is aged 10 to 17 inclusive, at time of signing consent/assent and completion of Visit 1 procedures.
- Youth meets full diagnostic criteria for primary Generalized Anxiety Disorder, Separation Anxiety Disorder, or Social Anxiety Disorder as assessed by the Anxiety Disorders Interview Schedule-IV (ADIS-IV) during Visit 1. Note: the ADIS diagnostic criteria are only valid for two weeks. For the purposes of our study, a youth should be randomized, have randomization revealed, and be in treatment (i.e., complete Visit 2) within 14 days of Visit 1 diagnostic/clinical interview. If this timeline is not met, clinical measures may need to be updated with the youth and parent/legal guardian, although consent does not need to be re-obtained. Parent and youth versions of the Screen for Child Anxiety Related Emotional Disorders, as well as the Pediatric Anxiety Rating Scale and Clinician's Global Impressions - Severity/Improvement Scale might also be re-administered. The ADIS will need to be reviewed to assess whether there have been any diagnostic changes during the elapsed time period. If more than one month has elapsed from the time of baseline, all measures within baseline procedures would be readministered, including reconsenting parent/legal guardian and youth. All such cases must be triaged in the next immediate weekly Project Management meeting.
- Youth otherwise meeting study entry criteria, who are receiving treatment for a stable medical or psychiatric condition, may be included providing that medication and dose have been stable for at least six weeks (e.g., stable dose of stimulant medication for Attention-Deficit/Hyperactivity Disorder) prior to study entry and remain stable on that medication and dose throughout their study participation. Changes to medication during study participation following randomization at Visit 2 will be considered non-urgent protocol deviations and will be tracked in the Protocol Deviations Form. Youth would not be removed from the study in this case, but their data may be excluded from sensitivity analyses.
- Youth must have a standard score of at least 85 on the Wechsler Abbreviated Scale of Intelligence, Vocabulary and Matrix Reasoning subtests, as well as the Wide Range Achievement Test-4 Reading subtest (administered during Visit 1) to ensure ability to read and understand stimuli during interpretation bias assessments and CBM-I.
- Youth must have access to a desktop or laptop computer and access to internet at home or can access one at their school or local library for the at-home portion of the computer training program. For youth without access, families can agree to complete all 16 CBM-I trainings (if randomized to CBM-I) at the BRAVE Lab.
Exclusion Criteria:
- Requires treatment other than CBM-I/CR: namely, youths with severe anxiety indicating need for higher level of care (e.g., psychiatric hospitalization), or primary major depressive disorder, bipolar disorder, psychosis, safety concerns due to recent or current acute suicidal ideation with plan, intent, and/or attempt that warrants alternate intervention, Posttraumatic Stress Disorder, substance dependence, current physical or sexual abuse, or intellectual disability. This will be determined during the Visit 1 ADIS interview. Consultation with the PI will occur in all cases where another mental health concern may be primary and/or warrant more immediate treatment.
- At Visit 1, is currently in alternate psychosocial intervention for any reason or has plans to initiate any psychosocial intervention for any reason.
- Has previously received any type of cognitive bias modification (attention or interpretation bias as target) at the BRAVE Lab or elsewhere.
- The family indicates they are no longer interested or able to participate in the study after Visit 1 (in which it is determined that the family is eligible) but before the family is randomized or told of their randomization. The youth will be excluded and not included in ITT analyses, and the randomization will be "thrown back" into the randomization scheme.
- Has significant uncorrected vision impairment (e.g., uncorrected blindness) that precludes participation in the computerized assessment and intervention components of the study.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：解釈のための認知バイアス修正 (CBM-I)
解釈の偏りを減らすことを目的とした、コンピューター化された 16 セッションの介入。
この研究では、CBM-I は若者の不安症状に合わせて個別化されています。
CBM-I セッション中、青少年は単語と文のペアが関連しているかどうかを示し、バイアスを減らすことを目的としたフィードバックが提供されます。
|
Computerized intervention in which youth see word-sentence pairs personalized to their anxiety symptoms, and indicate whether these are related.
Youth receive feedback aimed to reduce interpretation b
他の名前：
|
|
アクティブコンパレータ：Cognitive Restructuring (CR)
Four session psychosocial intervention aimed at reducing anxiety.
CR is a standard treatment technique (and often full intervention protocol) aimed at modifying anxious cognitions by teaching youth to identify when they make threat attributions, consider alternate non-threatening attributions, and thereby change their anxious thought processes, resultant avoidance, and anxiety symptoms.
|
Adapted from well-tested manual, The Coping Cat (child and adolescent versions), administered by trained, supervised therapists.
Duration of CR is matched to CBM-I in regard to total time in intervention across four weeks.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Linguistic Interpretation Bias as Assessed by the Word-sentence Association Paradigm for Youth (WSAP-Y)
時間枠：6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
The WSAP-Y is a computerized assessment of interpretation bias in which youth indicate whether word-sentence pairings are related.
This measure provides information about the degree to which youth evidence interpretation bias, as well as a behavioral (reaction time) index for bias endorsement.
For the primary outcome of percent threat interpretations endorsed, the possible range is 0 (zero) to 100%.
Higher percentage indicates more threat interpretation bias (i.e., the youth endorsed a higher proportion of threat words as related to ambiguous sentences); lower scores indicate lower threat interpretation bias.
Greater decrease in the percent of threat interpretations endorsed and lower absolute scores indicate "better" outcome (i.e., more reduction in threat interpretation bias; less interpretation bias overall).
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Change in Visual Interpretation Bias as Assessed by the Ambiguous Faces Task
時間枠：6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
Youth view faces portraying neutral expressions or subtle emotional expressions (i.e., morphed faces ranging in intensity of emotional valence).
Youth categorization of faces as neutral or threatening provides their sensitivity and bias for reporting presence of threat.
The criterion mean value in outcomes below reflects a score from -1 to 1, with higher negative numbers reflecting greater bias toward angry faces, and higher positive values approaching one reflecting a bias toward happy faces.
Theoretically, higher positive values indicate "better" outcome such that youth have more positive bias toward facial stimuli.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Change in Self-reported Interpretation Bias as Measured by the Children's Automatic Thoughts Scale (CATS)
時間枠：6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
The Children's Automatic Thoughts Scale is a youth self-report questionnaire which assesses presence and frequency of a variety of anxious thoughts from domains of: physical threat, social threat, personal failure, and anxious hostility.
Total scores range from 0 to 160, with higher scores indicating more threat interpretation bias.
Higher scores indicate "worse" outcome, or that youth self-report that they have more threatening thoughts and/or threatening thoughts at higher frequency; lower scores indicate "better" outcome or that youth self-report fewer threatening thoughts and/or threatening thoughts at lower frequency.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of CBM-I Trainings Completed of 16 Intended Sessions (CBM-I Arm Only)
時間枠：6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
This outcome is related to the "feasibility of CBM-I" aim.
The number of CBM-I trainings completed of 16 intended sessions.
Theoretically, completion of more training sessions is better and indicates that youth received a higher "dose" of training.
This outcome only applies to the CBM-I arm.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Participant/Parent Acceptability Questionnaire (PAQ)
時間枠：6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
The Participant Acceptability Questionnaire is a 8-item youth and parent report questionnaire, accompanied by an exit interview, that assesses burden (travel, boredom), credibility of computerized intervention techniques, and youth comprehension of the intervention.
Parents and youth complete the PAQ separately.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Anxiety symptom severity - PARS
時間枠：6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
Anxiety symptom severity as measured by clinician-administered Pediatric Anxiety Rating Scale (PARS).
Administered separately to parent and child, and scored by clinician by summing totals for the 7 items.
Scores range from 0-35, with higher scores suggesting higher/worse anxiety symptom severity.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
|
Anxiety symptoms - SCARED
時間枠：6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
Total anxiety symptoms as measured by the Screen for Anxiety Related Emotional Disorders (SCARED), 41-item version.
Each of 41 items ranges from 0-2, total anxiety symptoms calculated by scoring total across all 41 items.
Total scores range from 0-82, with higher scores suggesting more/worse anxiety symptoms.
|
6 weeks following randomization/start of treatment (post-treatment study visit at Week 6)
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年8月21日
一次修了 (推定)
2028年8月1日
研究の完了 (推定)
2028年8月1日
試験登録日
最初に提出
2026年8月28日
QC基準を満たした最初の提出物
2026年9月9日
最初の投稿 (実際)
2026年9月14日
学習記録の更新
投稿された最後の更新 (実際)
2026年9月14日
QC基準を満たした最後の更新が送信されました
2026年9月9日
最終確認日
2026年9月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 5R33MH121552 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
Data resulting from this project will be de-identified and uploaded in a timely manner to the National Database for Clinical Trials Related to Mental Illness, including de-identified youth demographic and clinical characteristics, and summary scores from outcome measures, along with a data dictionary that provides variable definitions, value labels, and scoring of measures.
The study protocol and dataset may be made available to other investigators based on successful completion of a data request form, following the conclusion of this study and publication of primary outcome papers.
IPD 共有時間枠
Data will become available following conclusion of the study and publication of primary outcome papers.
IPD 共有アクセス基準
Researchers will be required to complete a request form that includes: research identifying information and institutional affiliation, description of research objectives, and IRB approval.
Completed request forms will be reviewed by the PI and Co-Is to ensure that the research request will not duplicate work being conducted by the study team.
The requesting researcher must provide signed data sharing agreements from all users on their team outlining the details of how information will be kept secure, consistent with NIMH and University of Denver data sharing guidelines.
Requesting researchers will also provide the University of Denver's IRB with an IRB approval from their institution.
The data will only be released after the proposed study has been completed and primary outcomes have been accepted for publication.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。